DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Aromatase inhibitors (Cont.):
first generation, 1760f, 1761
nonsteroidal, 1760f, 1761
second generation, 1760f, 1761
steroidal, 1760f, 1761
therapeutic uses of, 1760
third generation, 1760f, 1761–1763
(See also Anastrozole;
Exemestane; Letrozole)
type 1, 1760f, 1761
type 2, 1760f, 1761
Aromatic hydroxylation, 127, 128t
Aromatic L-amino acid decarboxylase
(AADC), 197f, 336, 614–615
Arrhythmia(s), 815
afterdepolarization and, 820
common, 823, 824t–825t
drug-induced, 820, 821t, 830, 832,
833
drug therapy for, 815–848 (See also
Antiarrhythmic drugs)
enhanced automaticity and, 820
mechanism of, 820–823, 822f
reentry
anatomically defined, 823f
functionally defined, 823f
niacin-associated, 900
nontreatment, 832
precipitating factors
identification, 832
removal, 832
re-entrant, 820–823
symptoms due to, 832
treatment
approaches for, selection among,
832–833
goals, 832
principles of, 832–833
triggered automaticity and, 820
Arrythmias
ethanol and, 636
sympathomimetic drugs for, 302
Arsenic, 1867–1871
Arsenic antidote, 86t
Arsenic trioxide, 1723
Artemether-lumefantrine, 1389t
Artemisinin, 1386, 1395–1398
Arterial blood pressure, angiotensin II
and, 730
Arterial thrombosis, heparin-induced
thrombocytopenia and, 859
Artesunate, treatment regimen for,
1389t
Arthritis, psoriatic, biological agents
for, 1825t
ARTHROTEC, 987
Arthrus reactions, 76
Aryl hydrocarbon receptor (AHR),
140, 140t
ARZERRA (ofatumumab), 1747–1748
Arzoxifene, 1756
Ascariasis, 1444–1445
Ascaris lumbricoides, 1444–1445
Ascending thin limb (ATL), 673
Ascites, diuretics for, 699–701
Ascorbic acid (vitamin C), SLC
transporters and, 102t
Asenapine, 425t, 432t
Asian populations, mephenytoin
hydroxylase and, 157
Asinidione, structure of, 860f
L-Asparaginase, 1668t–1670t,
1720–1721
Aspartate
in central nervous system, 379–380
and vasopressin secretion, 704
Aspergillus terreus, 893
Aspirin, 977–982
absorption, 978
for angina, 767
antiplatelet effects, 849
site of action, 868f
in cancer prevention, 972–973
cardioprotective effect, 971–972
chemistry of, 977
COX isoform selectivity, 962f
cyclooxygenase inhibition, 964
distribution of, 978
dosage and administration of, 966t
drug interactions with, 981
elimination, 978
history of, 959
hypersensitivity, 975
and inhibition of eicosanoids, 941
intolerance, 975
low-dose, and NSAIDs, concomitant
therapy with, 976
manifestation of overdose
symptoms, 75t
mechanism of action of, 977–978
metabolism of, 128t
for myocardial ischemia, 752
pharmacokinetics of, 966t
pharmacology of, 962f
plasma pharmacokinetics of, 962f
resistance, 975
structure of, 977f
therapeutic uses of, 966t, 979
for myocardial ischemia, 771
Aspirin poisoning, 75
ASTELIN (azelastine hydrochloride),
922, 922t
Astemizole, 920, 924
ASTEPRO (azelastine), 922
Asthma
angina pectoris with, recommended
treatment for, 769t
eicosanoids and, 947
mechanisms of, 1031–1032
muscarinic antagonists and, 231
sympathomimetic drugs for, 302
ATABRINE (quinacrine), 1819
ATACAND (candesartan cilexetil), 738
ATARAX (hydroxyzine hydrochloride),
921t
Atazanavir, 1652–1653
Gilbert’s syndrome and, 133
pharmacokinetics of, 1815t
structure of, 1648f
Atenolol
ADME, 327
adrenergic receptors and, 207t
as antihypertensive agent, 774t
cardioprotective effects of, 767
pharmacokinetics of, 1815t
structure of, 311f
therapeutic uses of, 327, 831
Atherogenesis, 883
Atherosclerosis, 751
hyperlipidemia and, 884–892
plaque stability in
arterial wall biology and, 889–890
statins and, 895
Athletic performance, androgens and,
1203
ATIVAN (lorazepam), 466t
Atomoxetine, 402t
dosage of, 402t
pharmacokinetics of, 1815t
polymorphisms and response to,
159t
side effects of, 402t
Atopic dermatitis
azathioprine for, 1820–1821
calcineurin inhibitors for, 1822
cyclosporine for, 1821
H 1
receptor antagonists for, 922
IVIG for, 1827
mycophenolate mofetil for, 1823
photochemotherapy for, 1814
pimecrolimus for, 1822
Atorvastatin, 893
absorption, fate, and excretion of,
896
chemistry of, 894
2001
INDEX